Analiza is a US-based company specializing in physicochemical property and in-vitro ADME analyses for early-stage drug discovery. Since 1996, we’ve focused on fast turnaround, flexible service options, and affordable solutions to help pharma, biotech, and academic institutions make data-driven decisions that shape the future of medicine.
At Analiza, our mission is to provide the right data at the right time. We believe that rigorous, high-quality assays—delivered on tight timelines—are critical to accelerating therapeutic breakthroughs. By combining gold-standard methods with innovative automation, we empower researchers to make confident decisions earlier in the drug discovery cycle.
Founded in 1996 by Dr. Chait and Dr. Zaslavsky, Analiza pioneered the first automated, miniaturized shake-flask system for logD in 1999. Over the decades, we’ve continued to refine and expand our capabilities, working closely with major pharmaceutical companies and smaller biotech startups alike. From early collaborations with the National Institutes of Health to the development of our new AlphaLogD assay, our history demonstrates a commitment to advancing both industry best practices and scientific innovation.
Founded by Dr. Chait and Dr. Zaslavsky
Developed first automated miniaturized shake flask system for logD
Established first contract as service provider with major pharma
Completed Solubility project for NIH, >55K compounds posted to PubChem
Addition of Ultra High Accuracy QTOF-LCMS and ADME screening assays
Validated ElogD assay
AlphaLogD assay and publication
Analiza, Inc. is a leading analytical services organization dedicated to discovering, developing, and commercializing new technologies for the life sciences. Analiza provides integrated solutions to key applications in the pharmaceutical, biotechnology and diagnostics industries.
High-throughput assays for solubility, logD/logP, pKa, and more, leveraging miniaturized “gold-standard” protocols.
Comprehensive screenings—microsomal stability, plasma stability, and PAMPA—to predict in-vivo performance efficiently and cost-effectively.
Tailored projects, from forced degradation studies to method development, powered by state-of-the-art instrumentation (HPLC, UPLC, LC-QTOFMS).
Innovative assays for protein higher-order structure, enabling deeper insights for quality control, lot release, and biosimilarity assessment.
We're a functional service provider for some of the world's largest pharmaceutical companies, screening hundreds of compounds weekly.
Our flexible service options make us a top choice for small to mid-size companies needing services that cannot be conducted internally.
Our pricing makes us an affordable option for non-profit and academic institutions needing services that cannot be conducted internally.
Contact our team today to see how Analiza can accelerate your drug discovery program.
